Mizuho Medy Co Ltd
TSE:4595
Mizuho Medy Co Ltd
Total Equity
Mizuho Medy Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mizuho Medy Co Ltd
TSE:4595
|
Total Equity
¥18.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Terumo Corp
TSE:4543
|
Total Equity
¥1.5T
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Olympus Corp
TSE:7733
|
Total Equity
¥773.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
7%
|
|
|
Sysmex Corp
TSE:6869
|
Total Equity
¥500.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
JEOL Ltd
TSE:6951
|
Total Equity
¥149.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Total Equity
¥181.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
Mizuho Medy Co Ltd
Glance View
Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken and currently employs 173 full-time employees. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
See Also
What is Mizuho Medy Co Ltd's Total Equity?
Total Equity
18.7B
JPY
Based on the financial report for Dec 31, 2025, Mizuho Medy Co Ltd's Total Equity amounts to 18.7B JPY.
What is Mizuho Medy Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
38%
Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Mizuho Medy Co Ltd have been 9% over the past three years , 38% over the past five years .
